B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, with an estimated annual incidence of 4.2 per 100 000.1 The disease has a predilection for the elderly and is characterized by the progressive expansion of CD5-expressing B lymphocytes in the bone marrow, blood, and secondary lymphoid tissues. However, the clinical course is remarkably heterogeneous. Individuals with an indolent form may live more than 30 years after diagnosis and never require treatment, whereas patients with an aggressive subtype experience a much shorter survival of 6 to 8 years despite aggressive therapy.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.